Journey Medical
Logotype for Journey Medical Corp

Journey Medical (DERM) investor relations material

Journey Medical Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Journey Medical Corp
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Q3 revenue rose 8% YoY to $19.0M; Emrosi revenue grew 84% to $9.0M, and adjusted EBITDA was positive for a second consecutive quarter.

  • 9M revenue increased 17% to $53.4M, while net loss narrowed to $3.9M from $10.2M.

  • Emrosi demand, refill trends, prescriber growth and improving payer reimbursement mix supported momentum.

Financial highlights

  • Q3 product revenue was $18.9M, up 11% YoY; other revenue fell 93% to $42K as prior-year Cutia supply revenue did not recur.

  • Q3 GAAP net loss narrowed to $1.315M, or $0.05/share, from $2.315M, or $0.09/share; operating loss narrowed to $530K from $1.5M.

  • Gross margin was 69% versus 67% in Q3 2025, primarily reflecting Emrosi’s lower cost impact on cost of sales.

  • SG&A was $12.6M, up $0.5M YoY; it included a one-time $1.7M former-vendor settlement, partly offset by lower Emrosi launch costs.

  • Cash was $22.3M at Sept. 30, 2026, versus $24.1M at Dec. 31, 2025; working capital was $25.7M versus $29.4M.

Outlook and guidance

  • A national plan covering over 25M lives is expected to add Emrosi to its formulary in January 2027, with impact expected to begin in Q1.

  • Management expects ASP to rise and gross-to-net to improve as formulary wins flow through in 2027; Q1 deductible resets may delay the benefit.

  • Management is considering 2027 guidance and expects caution in H1 while assessing patient mix, formulary adoption and stabilization; SG&A as a share of revenue is expected to remain steady or decrease slightly.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Journey Medical earnings date

Logotype for Journey Medical Corp
Q4 202625 Mar, 2027
Journey Medical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Journey Medical earnings date

Logotype for Journey Medical Corp
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Journey Medical Corporation is a pharmaceutical company specializing in dermatological treatments. Its focus is on developing and commercializing products to address various skin conditions. The company's portfolio includes branded and generic prescription medications, such as Qbrexza, a medicated cloth for hyperhidrosis, and Accutane, a well-known oral treatment for severe acne. Other offerings include Amzeeq and Zilxi, both topical minocycline formulations for acne and rosacea, respectively, and Exelderm, an antifungal cream. The company is headquartered in Scottsdale, Arizona, and its shares are listed on the NASDAQ.